Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
201 hedge funds and large institutions have $2.02B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2018 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 66 increasing their positions, 65 reducing their positions, and 18 closing their positions.
111% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 18
110% more call options, than puts
Call options by funds: $18.5M | Put options by funds: $8.82M
10% more funds holding
Funds holding: 183 → 201 (+18)
2% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 65
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
3% less capital invested
Capital invested by funds: $2.08B → $2.02B (-$60.8M)
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$15.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$13.9M |
| 3 |
Millennium Management
New York
|
+$12.5M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$10.7M |
| 5 |
AC
Armistice Capital
New York
|
+$7.98M |
Top Sellers
| 1 |
SCM
Scopia Capital Management
New York
|
-$17.8M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$13.9M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$13.8M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$11.9M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$11.6M |
HZNP Hedge Fund Activity: Q1 2018 in Review
201 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q1 2018, worth a combined $2.02B — down 2.9% from $2.08B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new HZNP positions and 18 closed out — a net gain of 20 holders — while 66 added to existing stakes and 65 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $15.4M. The largest seller was Scopia Capital Management, cutting an estimated $17.8M.
- 201 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q1 2018, up from 183 in Q4 2017.
- Funds reported $2.02B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q1 2018, down 2.9% quarter-over-quarter.
- 38 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q1 2018 and 18 closed out, a net change of +20 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q1 2018 was Renaissance Technologies, an estimated $15.4M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q1 2018 was Scopia Capital Management, an estimated $17.8M sold.
Based on aggregated 13F filings for Q1 2018.